Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 19/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5166028 | 0.91 | TAS2R14 (0.48) | TAS2R14PTGESCXCR3 | |
| SCHEMBL4955541 | 0.81 | PTPRB (0.45) | PTGES | |
| SCHEMBL5165546 | 0.78 | PTPN1 (0.65) | TAS2R14MEN1KMT2ACXCR3 | |
| SCHEMBL5188296 | 0.78 | PTPN1 (0.62) | — | |
| SCHEMBL5177659 | 0.75 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL1615817 | 0.73 | TAS2R14 (1.00) | TAS2R14MEN1KMT2APTGESCXCR3 | |
| SCHEMBL1615515 | 0.73 | TAS2R14 (1.00) | TAS2R14MEN1KMT2ACXCR3 | |
| SCHEMBL1278788 | 0.73 | TAS2R14 (0.97) | TAS2R14MEN1KMT2APTGESCXCR3 | |
| SCHEMBL5499275 | 0.72 | FAAH (0.35) | KMT2APTGES | |
| SCHEMBL4903501 | 0.72 | ALDH1A1 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | TAS2R14 4230/4885MEN1 4371/4885KMT2A 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.